NCT06263244: Specifying the Anti-inflammatory Effects of Ziltivekimab
- State
- Completed
- Phase
- Phase 3
- People
- 40 taking part
- Started
- 3 May 2024
- Primary completion
- 30 Oct 2026
- Arms
- Ziltivekimab
- Results
- None posted
- 16 Feb 2024: Trial registered
- 3 May 2024: Trial started
- 30 Oct 2026: Trial completed